Exploring Therapeutic Potentials and Pathways of Psychedelics in Alzheimer’s Disease‐Related Dementia
Alzheimer s & Dementia December 1, 2024 Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh et al. 1 citation
Psychedelics such as DMT, LSD, and psilocybin, traditionally linked to recreational and spiritual use, are being investigated for therapeutic benefits in Alzheimer's disease-related dementia. These compounds act as serotonin agonists and enhance neural plasticity through serotonin and glutamate systems. They may modulate Alzheimer's-related signaling pathways, including the BDNF pathway, mTOR activation, and autophagy regulators. Controlled administration, depending on dosage, offers a potential novel intervention for dementia. The review highlights promising pathways but emphasizes the need for further studies to establish long-term safety, efficacy, and optimal treatment protocols.